【摘要】：目的:本試驗通過對主要療效指標及次要療效指標的觀察及分析,采用國際公認的診斷標準,療效評定標準,論證本課題促健顆粒治療CIS(痰瘀阻絡(luò)證)的臨床療效。方法:本課題從長春中醫(yī)藥大學(xué)附屬醫(yī)院腦病療區(qū)住院的病人中收治缺血性中風(fēng)恢復(fù)期(痰瘀阻絡(luò)證)的患者,將符合納入標準的60例患者隨機分為試驗組、對照組各30例,兩組患者都進行基礎(chǔ)治療,口服阿司匹林腸溶片,100mg,每日一次,試驗組在此基礎(chǔ)上加服促健顆粒,每日兩次,每次1份,療程8周加6個月隨訪,通過主要療效指標,發(fā)病180天時改良Rankin量表確定mRS≤2分的百分比及次要療效指標Barthel指數(shù),BI≥75分的比例、NIHSS量表及中醫(yī)證候療效判斷標準觀察對比兩組的療效差異,以論證促健顆粒的療效。結(jié)果:經(jīng)過臨床觀察及統(tǒng)計學(xué)分析,兩組患者從性別、年齡、病程上沒有統(tǒng)計學(xué)差異,兩組患者均具有臨床試驗可比性(P0.05);經(jīng)治療8周后兩組患者在改良Ra nkin量表評分、NIHSS評分、ADL評分及中醫(yī)證候?qū)W評分上沒有顯著差異(P0.05),但是兩組在第6個月隨訪時試驗組在改良Rankin量表上≤2分的比例高于對照組,試驗組在BI≥75的比例明顯高于對照組,試驗組在6個月隨訪時NIHSS評分、中醫(yī)證候?qū)W評分均優(yōu)于對照組(P0.05)。結(jié)論:促健顆粒治療缺血性中風(fēng)恢復(fù)期(痰瘀阻絡(luò)證)臨床療效顯著,效果優(yōu)于單純口服阿司匹林腸溶片,不僅能提高患者的生活能力且能降低患者的致殘率。
[Abstract]:Objective: through the observation and analysis of the main curative effect index and the secondary curative effect index, using the internationally accepted diagnostic standard and the curative effect evaluation standard, the clinical curative effect of the treatment of CIS (phlegm stasis obstruction collateral syndrome) by the Caijian granule was proved. Methods: 60 patients with ischemic apoplexy (phlegm and blood stasis syndrome) were randomly divided into experimental group (control group) and control group (30 cases each) from the patients in the encephalopathy treatment area of the affiliated Hospital of Changchun University of traditional Chinese Medicine (Changchun University of traditional Chinese Medicine). The patients in both groups were treated with basic treatment, oral aspirin enteric-coated tablets 100 mg, once a day. On this basis, the experimental group took Caijian granules twice a day, once a time, the course of treatment was 8 weeks and 6 months follow-up, through the main curative effect index, The percentage of mRS 鈮，

本文編號：2210790